AMFX-200 for Acute Spinal Cord Injury
Our lead candidate is a neuroregenerative treatment for acute spinal cord injury (SCI) and other neurological conditions
~18K people in the US, and ~500K globally, experience SCI each year leading to long-term paralysis
Disproportionately impacts younger people, with an average age at injury of only ~44 years old
There is no FDA-approved therapeutic available to restore function after SCI
AMFX-200 takes an entirely new approach to neural regeneration by combining pharmacological action of peptide drugs and a nanofiber scaffold into one therapy
Demonstrates unprecedented motor function recovery in preclinical models of SCI
Reduces neuropathic pain and inflammatory responses in the spinal cord
Prevents formation of glial scar tissue which inhibits neural function
Representative recovery of motor function in preclinical model of acute SCI:
Control mice (left) have no hind limb function after injury. Mice treated with AMFX-200 (right) recover significant motor function, including plantar stepping and weight bearing in their hind limbs.
Video credit: Northwestern University.
Learn more:
AMFX-100 for Spinal Fusion Surgery
Our off-the-shelf bone graft substitute enables orthopedic surgeons to perform spinal fusion procedures without using donor tissue or recombinant proteins
~0.5 million spinal fusion procedures are performed each year in the US
Fusion procedures are used to treat back pain caused by degenerative disc disease
Current approaches such as recombinant proteins have safety issues that limit their use
AMFX-100 has received a Breakthrough Device Designation from the FDA
Representative bone growth in preclinical sheep model of interbody spinal fusion:
Micro-CT
Histology
When implanted between vertebrae after removal of a diseased disc, AMFX-100 generates new bone tissue to fuse vertebrae together, as seen in CT and histology images.